{"id":48192,"date":"2022-09-09T22:01:44","date_gmt":"2022-09-09T20:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adding-and-replacing-convert-clinical-trial-data-presented-at-ers-demonstrates-early-success-of-aeriseal-system-in-patients-with-advanced-copd-emphysema\/"},"modified":"2022-09-09T22:01:44","modified_gmt":"2022-09-09T20:01:44","slug":"adding-and-replacing-convert-clinical-trial-data-presented-at-ers-demonstrates-early-success-of-aeriseal-system-in-patients-with-advanced-copd-emphysema","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adding-and-replacing-convert-clinical-trial-data-presented-at-ers-demonstrates-early-success-of-aeriseal-system-in-patients-with-advanced-copd-emphysema\/","title":{"rendered":"ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD\/Emphysema"},"content":{"rendered":"
\n

\nThe reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System<\/i>\n<\/p>\n

REDWOOD CITY, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–$LUNG<\/a> #COPD<\/a>–Please note the addition of citations at the end of the release dated Sept. 4, 2022.\n<\/p>\n

<\/a><\/p>\n

\nThe updated release reads:\n<\/p>\n

\nCONVERT CLINICAL TRIAL DATA PRESENTED AT ERS DEMONSTRATES EARLY SUCCESS OF AERISEAL SYSTEM IN PATIENTS WITH ADVANCED COPD\/EMPHYSEMA<\/b>\n<\/p>\n

\nThe reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System<\/i>\n<\/p>\n

\nPulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation (CV) status in 78% of patients who were subsequently treated with Zephyr Valves.\n<\/p>\n

\nThe AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD\/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. Patients whose lungs have untreated collateral ventilation (CV+) are currently ineligible for treatment with Zephyr Valves and have limited options once medical management alone does not control symptoms. Once the target lobe is converted from CV+ to CV-, patients can be treated with Zephyr Valves, which has been shown to improve lung function, quality of life, and exercise capacity for patients with severe COPD\/emphysema.1<\/sup>\n<\/p>\n

\nThe CONVERT study uses the AeriSeal System to close collateral air flow. Once the treated lobe tests negative for collateral ventilation (CV-), Zephyr Valves are implanted to address hyperinflation of that target lobe to ease emphysema symptoms without major surgery. Successfully converted patients who received Zephyr Valves had clinically meaningful Target Lobe Volume Reduction (TLVR) with a mean reduction of greater than one (1) liter. The CONVERT trial is ongoing and full clinical outcomes of BLVR with Zephyr Valves were not reported at this time. However, results recently published from a single-center feasibility study at Macquarie University Hospital in Australia showed that the AeriSeal System successfully closed collateral air channels and allowed for successful clinical outcomes after treatment with Zephyr Valves.2<\/sup> At 6 months, AeriSeal and Zephyr Valve treated CV+ patients experienced clinically meaningful improvements similar to improvements in CV- patients treated with Zephyr Valves alone.2 <\/sup>Improvements included:\n<\/p>\n